A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...
A novel topical gel, HT-001, shows promise as a treatment for cutaneous side effects caused by epidermal growth factor receptor inhibitor (EGFRi) cancer therapy. According to a press release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results